Download full-text PDF |
Source |
---|
Allergol Select
October 2023
Department of Dermatology and Allergology, University Hospital Giessen, Justus Liebig University Gießen, Gießen, Germany.
Aesthetic Plast Surg
February 2024
Division of Allergy and Immunology, Department of Otolaryngology, The Ohio State University, 915 Olentangy River Rd, Columbus, OH, 43212, USA.
Background: Hyaluronidase is used as a reversal agent for hyaluronic acid fillers and to increase the diffusion of other medications after infiltration. Cases of hyaluronidase allergy have been described in the literature since 1984. However, it is still frequently misdiagnosed.
View Article and Find Full Text PDFSingapore Med J
December 2024
Department of Otolaryngology, Lewisham and Greenwich NHS Trust, London, United Kingdom.
Introduction: Localised swelling at sites of filler injections has been reported in the Moderna mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine trial.
Methods: We conducted a review of the existing data and literature on the potential pathophysiology for this adverse event and its potential management.
Results: Data from the Moderna and Pfizer COVID-19 vaccine Phase 3 trial and one case series were available.
J Cosmet Dermatol
December 2022
Department of Oral & Maxillofacial Surgery, Faculdade Patos de Minas, Brasília, Brazil.
Objectives: The aim of this article is to report a case of iatrogenic Cushing's disease associated with a delayed inflammatory response due to a facial dermal filler procedure.
Methods: A case report according to CARE guidelines was performed. A delayed inflammatory reaction due to dermal filler injection resulted in iatrogenic Cushing's disease in a patient with no comorbidities or allergies.
Drug Metab Pers Ther
December 2020
Halozyme Therapeutics Inc., San Diego, CA, USA.
Objectives: Drug-drug interaction studies for hyaluronidase safety assessments have evaluated only animal-derived enzyme preparations. We therefore set out to evaluate whether high-dose administration of two antihistamines, a potent corticosteroid, steroid hormone, adrenocorticotropic hormone (ACTH), or salicylic acid would alter the dispersive activity of recombinant human hyaluronidase PH20 (rHuPH20).
Methods: NCr nu/nu mice were pretreated with diphenhydramine, cetirizine, dexamethasone, estrogen, ACTH, salicylic acid, and/or neutral-buffered saline (NBS).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!